Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) went down by -4.23% from its latest closing price compared to the recent 1-year high of $24.18. The company’s stock price has collected -3.81% of loss in the last five trading sessions. Press Release reported on 09/15/21 that Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
Is It Worth Investing in Aurinia Pharmaceuticals Inc. (NASDAQ :AUPH) Right Now?
Plus, the 36-month beta value for AUPH is at 0.34. Opinions of the stock are interesting as 7 analysts out of 8 who provided ratings for Aurinia Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $30.00, which is -$8.2 below the current price. AUPH currently public float of 117.64M and currently shorts hold a 15.50% ratio of that float. Today, the average trading volume of AUPH was 4.17M shares.
AUPH’s Market Performance
AUPH stocks went down by -3.81% for the week, with a monthly drop of -6.19% and a quarterly performance of 69.68%, while its annual performance rate touched 27.18%. The volatility ratio for the week stands at 4.72% while the volatility levels for the past 30 days are set at 7.51% for Aurinia Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -8.55% for AUPH stocks with a simple moving average of 33.87% for the last 200 days.
Analysts’ Opinion of AUPH
Many brokerage firms have already submitted their reports for AUPH stocks, with H.C. Wainwright repeating the rating for AUPH by listing it as a “Buy.” The predicted price for AUPH in the upcoming period, according to H.C. Wainwright is $35 based on the research report published on January 25th of the current year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $28, previously predicting the price at $34. The rating they have provided for AUPH stocks is “Buy” according to the report published on November 03rd, 2020.
BTIG Research gave a rating of “Buy” to AUPH, setting the target price at $20 in the report published on June 17th of the previous year.
AUPH Trading at 5.19% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.53% of loss for the given period.
Volatility was left at 7.51%, however, over the last 30 days, the volatility rate increased by 4.72%, as shares sank -5.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.62% upper at present.
During the last 5 trading sessions, AUPH fell by -3.81%, which changed the moving average for the period of 200-days by +42.44% in comparison to the 20-day moving average, which settled at $21.48. In addition, Aurinia Pharmaceuticals Inc. saw 42.44% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at AUPH starting from Huizinga Robert Bindert, who sale 32,500 shares at the price of $23.99 back on Sep 21. After this action, Huizinga Robert Bindert now owns 100,728 shares of Aurinia Pharmaceuticals Inc., valued at $779,533 using the latest closing price.
Martin Michael Robert, the Chief Business Officer of Aurinia Pharmaceuticals Inc., sale 87,500 shares at $24.02 during a trade that took place back on Sep 21, which means that Martin Michael Robert is holding 176,861 shares at $2,101,750 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- -194.50 for the present operating margin
The net margin for Aurinia Pharmaceuticals Inc. stands at -204.88. The total capital return value is set at -28.27, while invested capital returns managed to touch -29.81.
Based on Aurinia Pharmaceuticals Inc. (AUPH), the company’s capital structure generated 2.06 points at debt to equity in total, while total debt to capital is 2.02. Total debt to assets is 1.81, with long-term debt to equity ratio resting at 1.87. Finally, the long-term debt to capital ratio is 1.83.
When we switch over and look at the enterprise to sales, we see a ratio of 24.91, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 72.32 and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.11.